Beneficial Effect of TRAIL on HIV Burden, without Detectable Immune Consequences

Open Access

Peer-reviewed

Research Article

Brett D. Shepard,

Affiliation Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Davide De Forni,

Affiliation Virostatics s. r. l., Sassari, Italy
⨯
David R. McNamara,

Affiliation Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Andrea Foli,

Affiliation Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
⨯
Stacey A. Rizza,

Affiliation Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Roshini S. Abraham,

Affiliation Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Keith Knutson,

Affiliation Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Peter J. Wettstein,

Affiliation Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Franco Lori,

Affiliation Research Institute for Genetic and Human Therapy, Pavia, Italy
⨯
Andrew D. Badley

* E-mail: badley.andrew@mayo.edu

Affiliation Mayo Clinic, Rochester, Minnesota, United States of America
⨯

Reader Comments (0)

T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
Cytokine therapy
Is the Subject Area "Cytokine therapy" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
Viral load
Is the Subject Area "Viral load" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Lymphocytes
Is the Subject Area "Lymphocytes" applicable to this article?

Thanks for your feedback.
HIV infections
Is the Subject Area "HIV infections" applicable to this article?

Thanks for your feedback.